Product royalty revenues — Total revenues
Incyte Product royalty revenues — Total revenues decreased by 17.9% to $151.19M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 15.7%, from $130.62M to $151.19M. Over 4 years (FY 2021 to FY 2025), Product royalty revenues — Total revenues shows an upward trend with a 2.8% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates successful commercialization of licensed assets by partners and growing market adoption of the underlying therapies. A decrease may signal declining demand for the licensed products, patent expirations, or changes in royalty agreement terms.
Detailed definition
This metric represents the total revenue generated from licensing intellectual property and drug development rights to t...
Peer comparison
Comparable to royalty income or licensing revenue reported by other biotechnology firms that utilize a hybrid model of internal commercialization and external licensing partnerships.
incy_segment_product_royalty_revenues_total_revenuesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $120.56M | $183.97M | $164.82M | $122.41M | $117.55M | $110.29M | $132.49M | $115.44M | $127.61M | $130.83M | $149.61M | $125.97M | $137.19M | $156.88M | $159.29M | $130.62M | $151.12M | $171.12M | $184.05M | $151.19M |
| QoQ Change | — | +52.6% | -10.4% | -25.7% | -4.0% | -6.2% | +20.1% | -12.9% | +10.5% | +2.5% | +14.4% | -15.8% | +8.9% | +14.3% | +1.5% | -18.0% | +15.7% | +13.2% | +7.6% | -17.9% |
| YoY Change | — | — | — | — | -2.5% | -40.0% | -19.6% | -5.7% | +8.6% | +18.6% | +12.9% | +9.1% | +7.5% | +19.9% | +6.5% | +3.7% | +10.1% | +9.1% | +15.5% | +15.7% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Incyte's product royalty revenues — total revenues?
- Incyte (INCY) reported product royalty revenues — total revenues of $151.19M in Q1 2026.
- How has Incyte's product royalty revenues — total revenues changed year-over-year?
- Incyte's product royalty revenues — total revenues increased by 15.7% year-over-year, from $130.62M to $151.19M.
- What is the long-term trend for Incyte's product royalty revenues — total revenues?
- Over 4 years (2021 to 2025), Incyte's product royalty revenues — total revenues has grown at a 2.8% compound annual growth rate (CAGR), from $569.26M to $636.91M.
- What does product royalty revenues — total revenues mean?
- Revenue earned from royalties on products licensed to and sold by other pharmaceutical companies.